Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 trial of intranasal or intramuscular GEM-adjuvanted seasonal influenza vaccine in healthy adults
NL-OMON36678Phase 1Active, not recruiting
- Sponsor
- Mucosis B.V.
- Start
- Mar 2011
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of trivalent inactivated influenza vaccine in influenza (8 arms), sponsored by Mucosis B.V. Primary endpoints: Safety and tolerability and Reactogenicity. Started Mar 2011; status: active, not recruiting.
02
Drugs
trivalent inactivated influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NL-OMON36678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36678.